Organism: Homo sapiens
Gene: 39032_at
Selected probe(set): 215111_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39032_at (215111_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):4.1040945
Number of Samples:9 / 3

Experimental	coronary artery disease study 2
	133+ endothelial progenitor cells obtained from patients with coronary artery disease (CAD) prior to exercise. CAD patients were enrolled in a cardiac rehabilitation program. Medical management was stable for at least 1 month prior to program participation. Baseline testing was performed after an overnight fast (except for water).
Control	normal endothelial progenitor cell (133+) sample
	133+ endothelial progenitor cells obtained from healthy subjects.

Relative Expression (log2-ratio):3.9627695
Number of Samples:2 / 2

Experimental	A. fumigatus study 1
	5 x 106 immature dendritic cells were cultivated together with 5 x 106 A. fumigatus germ tubes for 6h until isolation of total RNA.
Control	uninfected immature dendritic cell sample
	5 x 106 immature dendritic cells were cultivated without fungi.

Relative Expression (log2-ratio):-3.9534836
Number of Samples:3 / 3

Experimental	cell cycle inhibition study 1
	Human ovarian carcinoma cells (A2780) exposed to 3 micromolar of a cell cycle inhibitor for 6hrs.
Control	untreated A2780 ovarian carcinoma cell sample
	Untreated human ovarian carcinoma cells (A2780).

Relative Expression (log2-ratio):-3.9154854
Number of Samples:2 / 4

Experimental	R547 study 1 (24h)
	Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control	vehicle (DMSO) treated DU145 cell sample
	Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

Relative Expression (log2-ratio):3.5359707
Number of Samples:2 / 2

Experimental	connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control	connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.

Relative Expression (log2-ratio):-3.4999847
Number of Samples:4 / 4

Experimental	R547 study 1 (6h)
	Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control	vehicle (DMSO) treated DU145 cell sample
	Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.

Relative Expression (log2-ratio):-3.3316784
Number of Samples:3 / 3

Experimental	actinomycin D study 1
	A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. ATC code:
Control	mannitol treated A549 cell sample
	A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture.

Relative Expression (log2-ratio):-3.2539797
Number of Samples:3 / 3

Experimental	echinomycin study 1
	Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control	deferoxamine study 5
	Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

Relative Expression (log2-ratio):3.1119976
Number of Samples:6 / 6

Experimental	rosiglitazone study 5 (late)
	Monocytes, cultured with 2.5 uM rosiglitazone (RSG) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. ATC code:
Control	IL-4; GM-CSF study 1 (late)
	Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.

Relative Expression (log2-ratio):3.0664282
Number of Samples:3 / 3

Experimental	rosiglitazone study 4
	Monocytes were cultured for 5 days with 500 U/ml IL-4 and 800 U/ml GM-CSF, cytokine treatment was repeated at day 3. Rosiglitazone (RSG; 2.5 uM) was added at the beginning of differentiation. ATC code:
Control	vehicle (DMSO/EtOH)/ IL-4/ GM-CSF treated monocyte sample
	Monocytes were cultured for 5 days with 500 U/ml IL-4 and 800 U/ml GM-CSF, cytokine treatment was repeated at day 3. Vehicle (DMSO/ethanol) was added at the beginning of differentiation.